Adam H. Golden

Adam H. Golden

Partner
New York

Email adam.golden@​hoganlovells.com

Phone +1 212 918 3636

Fax +1 212 918 3100

Practice groupCorporate & Finance

Head of the Corporate & Finance practice group in New York, Adam Golden advises life sciences companies on some of their most important transactions. Clients turn to Adam for his dual skillset, which combines his strengths as an M&A and corporate lawyer with those of an IP transactions lawyer. This enables him to represent pharmaceutical, biotech, and medical device companies in the full scope of transactions that are common to this sector.

Over his career, Adam has advised clients on M&A, license and collaboration deals, venture capital financings, and commercial transactions. Frequently, clients seek his advice on hybrid transactions such as M&A transactions with back-end milestone payments or contingent value rights, options to acquire companies or technology, and product divestitures. He also advises clients on the transition service, manufacturing and supply, and other operational agreements that often accompany these transactions.

Adam is recognized as a leading practitioner in Chambers Global, Chambers USA, Legal 500 US, Who's Who Legal, LMG Life Sciences, and IAM Patent 1000. In 2018, he was named M&A Attorney of the Year by LMG Life Sciences, and a Life Sciences MVP by Law360.

Awards and recognitions

2020

Life Sciences: Corporate/Commercial (USA)
Chambers Global

2009-2020

Life Sciences: Corporate/Commercial (Nationwide)
Chambers USA

2015-2018

Life Sciences: Corporate/commercial (Global-wide)
Chambers Global

2014-2020

Healthcare: Life Sciences, Leading Lawyer
Legal 500 US

2017-2020

M&A/Corporate and Commercial: M&A: Large Deals ($1bn+)
Legal 500 US

2012-2019

Life Sciences Star - Finance & Transactional
LMG Life Sciences

2018-2020

Life Sciences - Transactional
Who's Who Legal

2012-2018

The World's Leading Patent Practitioners
IAM Patent 1000

2020

Healthcare: life sciences, Recommended
Legal 500 US

Education and admissions

Education

J.D., New York University School of Law, 1990

A.B., Princeton University, 1986

Bar admissions and qualifications

New York

Massachusetts

Representative experience

Novartis on its acquisition of IFM Tre for up to US$1.6bn and its option to acquire IFM Due for up to US$840m.

Celgene Corporation, on its US$9bn acquisition of Juno Therapeutics, a clinical-stage cell immunotherapy company.

Novartis, on its US$8.7bn acquisition of AveXis Inc., a clinical-stage gene therapy biotech company.

Shire on the ex-U.S. aspects of its US$2.4bn oncology business sale to Servier S.A.S.

Celgene Corporation, on its acquisition of Impact Biomedicines for up to US$7bn, a clinical stage company developing fedratinib for myelofibrosis.

Chase Pharmaceuticals on its sale to Allergan for up to US$1bn.

Allergan on its US$40.5bn generics divestiture to Teva Pharmaceuticals.

Alcon Laboratories on its acquisitions of Encore Vision, RxSight, and Transcend Medical.

Novartis in the acquisition from GSK of rights to Arzerra® (ofatumumab) for auto-immune indications for more than US$1bn.

Kite, a Gilead company, in an up to US$3bn deal to access Sangamo Therapeutics' zinc finger nuclease technology.

Celgene on strategic collaborations and equity investments, including with Kyn Therapeutics, Ex Scientia, Obsidian Therapeutics, Jounce Therapeutics, and Skyhawk Therapeutics.

Gilead Sciences on its US$150m collaboration with Agenus to develop and commercialize up to five novel immuno-oncology therapies.

Novartis on its collaboration with Cellular Biomedicine Group to support the introduction of the CAR-T cell therapy Kymriah® (tisagenlecleucel) in China.

Gilead Sciences on its strategic partnership with Goldfinch Bio, to develop and commercialize innovative therapeutics for kidney diseases.

Bausch Health (formerly Valeant) on the sale of Dendreon Pharmaceuticals to the Sanpower Group Co., Ltd., one of the largest privately owned conglomerates in China.

Gilead Sciences on its strategic collaboration with Tango Therapeutics, to develop and commercialize innovative targeted immuno-oncology treatments for cancer.

Novartis on strategic collaborations with Surface Therapeutics, Xencor, and Homology Medicines.

Novartis in connection with its landmark portfolio transformation transactions with GSK and Eli Lilly worth more than US$23bn.

Buyers and sellers of FDA priority review vouchers.

Loading data